Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2004

Radiolabeled RGD-DTPA-Tyr 3 -Octreotate for Receptor-Targeted Radionuclide Therapy

Bert Bernard, Astrid Capello, Martin van Hagen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2008

Comparison of [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotate and [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotide for Receptor-Mediated Radiation Therapy of the Xenografted Human Midgut Carcinoid Tumor GOT1

Christina Swärd, Peter Bernhardt, Viktor Johanson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Biodistribution and Dosimetry of 177 Lu-Labeled [DOTA 0,Tyr 3 ]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2002

Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats

M. Laznicek, A. Laznickova, H. R. Mäcke [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2004

99m Tc-N 4 -[Tyr 3 ]Octreotate Versus 99m Tc-EDDA/HYNIC-[Tyr 3 ]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy

Michael Gabriel, Clemens Decristoforo, Theodosia Maina [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2015

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Phillip G. Claringbold, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2005

Differences in Biodistribution Between 99m Tc-Depreotide,111 In-DTPA-Octreotide,and 177 Lu-DOTA-Tyr 3 -Octreotate in a Small Cell Lung Cancer Animal Model

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessCase reportFirst published 2025

Squamous cell carcinoma diagnosed as a suspected neuroendocrine tumor by gallium-68 DOTA-Tyr 3 -octreotate positron emission tomography scan: A case report

Tori Johnson, Shirley Chan-Sanchez, Tuan Pham [...]

Sage Open Medical Case Reports

Restricted accessResearch articleFirst published November, 2012

Phase I-II Study of Radiopeptide 177 Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

Phillip G. Claringbold, Richard A. Price, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2004

Radiolabeled RGD-DTPA-Tyr 3 -Octreotate for Receptor-Targeted Radionuclide Therapy

Bert Bernard, Astrid Capello, Martin van Hagen [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2008

Comparison of [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotate and [ 177 Lu-DOTA 0,Tyr 3 ]-Octreotide for Receptor-Mediated Radiation Therapy of the Xenografted Human Midgut Carcinoid Tumor GOT1

Christina Swärd, Peter Bernhardt, Viktor Johanson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2003

Tyr 3 -Octreotide and Tyr 3 -Octreotate Radiolabeled with 177 Lu or 90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro

Astrid Capello, Eric P. Krenning, Wout A.P. Breeman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2003

Biodistribution and Dosimetry of 177 Lu-Labeled [DOTA 0,Tyr 3 ]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2002

Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats

M. Laznicek, A. Laznickova, H. R. Mäcke [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2004

99m Tc-N 4 -[Tyr 3 ]Octreotate Versus 99m Tc-EDDA/HYNIC-[Tyr 3 ]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy

Michael Gabriel, Clemens Decristoforo, Theodosia Maina [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published August, 2015

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Phillip G. Claringbold, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2005

Differences in Biodistribution Between 99m Tc-Depreotide,111 In-DTPA-Octreotide,and 177 Lu-DOTA-Tyr 3 -Octreotate in a Small Cell Lung Cancer Animal Model

Anneli Schmitt, Peter Bernhardt, Ola Nilsson [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessCase reportFirst published 2025

Squamous cell carcinoma diagnosed as a suspected neuroendocrine tumor by gallium-68 DOTA-Tyr 3 -octreotate positron emission tomography scan: A case report

Tori Johnson, Shirley Chan-Sanchez, Tuan Pham [...]

Sage Open Medical Case Reports

Restricted accessResearch articleFirst published November, 2012

Phase I-II Study of Radiopeptide 177 Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

Phillip G. Claringbold, Richard A. Price, J. Harvey Turner

Cancer Biotherapy and Radiopharmaceuticals